HC Wainwright Reiterates Buy Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $16.00 price objective on the stock.

AC Immune Stock Up 1.4 %

NASDAQ:ACIU traded up $0.03 on Friday, reaching $2.24. The stock had a trading volume of 195,766 shares, compared to its average volume of 330,418. The company has a market capitalization of $224.92 million, a P/E ratio of -4.87 and a beta of 1.23. AC Immune has a 1-year low of $2.16 and a 1-year high of $4.98. The stock has a fifty day moving average price of $2.60 and a 200-day moving average price of $2.97.

Hedge Funds Weigh In On AC Immune

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its position in shares of AC Immune by 6.4% during the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company's stock worth $220,000 after purchasing an additional 3,499 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in shares of AC Immune during the fourth quarter worth approximately $27,000. Two Sigma Advisers LP acquired a new position in shares of AC Immune during the fourth quarter worth approximately $36,000. Boothbay Fund Management LLC acquired a new position in shares of AC Immune during the fourth quarter worth approximately $38,000. Finally, RPO LLC acquired a new position in shares of AC Immune during the fourth quarter worth approximately $51,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.